Follow-on biologics hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
|Format:||Government Document Online Book|
|Series:||S. hrg. ;
|Online Access:||ONLINE VERSION|
No Tags, Be the first to tag this record!